Bracco Imaging S.p.A., an esteemed leader in the field of diagnostic imaging, has achieved a significant milestone with the European Commission’s recent amendment to the marketing authorization for Vueway (gadopiclenol). This extension now permits its use in pediatric patients under the age of two throughout the European Union (EU). This decision follows a favorable recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which evaluated the safety and efficacy of Vueway for this vulnerable population.
Innovative Contrast Agent
Vueway is a cutting-edge macrocyclic gadolinium-based contrast agent (GBCA) that has already received approval in 36 countries. Its primary function is to enhance contrast during magnetic resonance imaging (MRI) examinations, allowing healthcare providers to detect and diagnose various medical conditions that may otherwise remain undetected. Prior to this extension, the agent was approved for use in adults and children aged two years and older since December 2023, focusing on improving the visualization of pathologies associated with disruptions in the blood-brain barrier and abnormal vascularity.
Positive CHMP Opinion
On December 11, 2025, the CHMP endorsed the extension of Vueway’s approved indications to include infants and young children, which includes neonates. This decision underscores the established safety profile and diagnostic efficacy of this innovative GBCA. Such an extension is pivotal, as it addresses the pressing need for effective imaging solutions in younger patients who are at higher risk during diagnostic procedures.
Enhanced Safety Profile
Vueway is noted for its remarkable stability as a macrocyclic GBCA, boasting the highest longitudinal relaxivity (r1) values among currently approved GBCAs. Clinical studies conducted across multiple centers have demonstrated that Vueway offers comparable diagnostic effectiveness at a significantly reduced gadolinium dosage—specifically, half that of gadobutrol, a commonly used GBCA. This reduction in dosage is particularly beneficial in minimizing patient exposure to gadolinium, thus enhancing safety.
Clinical Importance of Reduced Gadolinium Exposure
Alberto Spinazzi, Chief Medical & Regulatory Officer of Bracco Group, emphasized the importance of minimizing gadolinium exposure without compromising diagnostic quality. This concern is especially relevant for special patient populations, including neonates and infants, whose developing brains and body tissues may be more susceptible to the potential long-term effects of retained gadolinium. The recent approval not only addresses a critical clinical need but also reflects Bracco’s commitment to patient safety.
GBCAs in Diagnostic Imaging
Gadolinium-based contrast agents, including Vueway, play a crucial role in the enhancement of MRI examinations. Gadolinium, a rare earth element, possesses unique magnetic properties that make it particularly effective for imaging applications. The routine use of GBCAs has significantly improved diagnostic performance in various medical settings, thereby facilitating timely and accurate patient assessments.
Bracco Imaging’s Commitment to Innovation
Bracco Imaging remains dedicated to advancing the field of diagnostic imaging, with a mission to enhance patient outcomes through innovative solutions. The company’s extensive portfolio includes a variety of pharmaceutical products tailored for diagnostic imaging, such as contrast agents for X-ray, Computed Tomography (CT), and MRI, along with microbubbles for contrast-enhanced ultrasound and molecular imaging through radioactive tracers. By focusing on precision medicine, Bracco is actively shaping the future of healthcare.
Conclusion
The European Commission’s extension of Vueway’s marketing authorization to include pediatric patients under two years old marks a significant advancement in diagnostic imaging. With its enhanced safety profile and proven efficacy, Vueway stands to transform the landscape of pediatric MRI, ensuring that even the youngest patients receive the highest quality of care. Bracco Imaging’s commitment to innovation and patient safety continues to drive progress in the field of diagnostic imaging.
- Bracco Imaging receives EU approval for Vueway’s use in infants and young children.
- Vueway boasts superior safety and efficacy at reduced gadolinium doses.
- The extension addresses critical needs in pediatric diagnostics.
- GBCAs enhance MRI performance and improve patient outcomes.
- Bracco Imaging is committed to advancing diagnostic imaging technologies.
Read more → www.pharmabiz.com